The New Bottleneck Nobody Budgeted For | NPLUS Global

We used to build outbound timelines backward from the send date. Now we build them backward from legal's calendar, and honestly, that shift has been the single biggest planning change we've made in the last year.

It didn't happen all at once. For a long time, compliance review on healthcare outbound campaigns was a formality — someone skimmed the copy, checked for obvious HIPAA landmines, maybe flagged a claim that sounded too aggressive, and things moved on within a day or two. That cadence started breaking down sometime in 2024 and by now, heading into 2026, it's basically gone. What used to be a 24-to-48-hour rubber stamp has, on several campaigns we've touched this year, stretched into a five-to-ten business day review cycle, sometimes longer if the campaign touches multiple state jurisdictions or involves any language that could be read as a clinical claim.

The reason isn't mysterious. State-level health data privacy laws have multiplied, enforcement bodies have gotten more aggressive about outbound marketing that references patient populations or clinical specialties, and legal teams inside health systems and payer organizations have — understandably — stopped taking risks on ambiguous copy. We had a campaign earlier this year for a client selling into hospital supply chain roles where the subject line mentioned "reducing readmission costs." Six words. It sat in review for eleven days because someone in compliance wanted to confirm the phrase didn't imply a clinical outcomes claim that would need substantiation. Eleven days for six words. That's the environment now.

Why "Send It Friday" Doesn't Work Anymore

The old outbound rhythm assumed you could write copy on Monday, get it approved by Wednesday, and be in market by Friday. That rhythm is dead for anything touching healthcare, and teams that haven't adjusted their internal planning are the ones we see scrambling most.

What's actually happening is that compliance review has stopped being a single gate and become a layered process. First there's internal legal review at the vendor or agency level. Then, if the campaign is going out under a health system's name or referencing their brand, there's a second review from that organization's own compliance or marketing governance team. Then, increasingly, there's a third pass if the campaign touches any state with its own health information privacy statute that's stricter than HIPAA baseline — and there are more of those states every year. Each layer adds its own queue, its own turnaround expectations, and its own set of stakeholders who may not be available the week you need them.

We've started treating compliance review the way we'd treat a shipping dependency in a supply chain — something with lead time that has to be modeled, not something you request and hope comes back fast. Campaigns that used to have a two-week runway now realistically need three to four weeks if there's any legal ambiguity in the messaging or targeting criteria. And targeting criteria is its own conversation now, because compliance teams are asking harder questions about how contact data was sourced, whether specialty or role targeting implies any inference about patient populations, and whether consent language on the list itself holds up to scrutiny.

The Data Sourcing Question Keeps Coming Up

Here's something that surprised us at first but makes complete sense in hindsight: a growing share of the review delay isn't about the copy at all. It's about the list.

Compliance and legal reviewers have started asking pointed questions about provenance — where did these contacts come from, what was the original consent basis, has the data been refreshed since it was collected, and does the targeting logic itself create any risk. If a campaign is targeting, say, oncology practice administrators specifically because of a data field that ties back to something more clinically sensitive than job title and specialty, that gets flagged. We've seen review cycles extend simply because the compliance team wanted documentation on data sourcing methodology before they'd sign off on messaging that seemed completely benign on its own.

This is part of why we've leaned harder into working with data partners who can actually answer sourcing questions in plain language — not marketing language, but the kind of specific, boring detail a compliance officer wants: how the record was verified, when, and under what basis. NPLUS Global's approach to this has been useful internally precisely because it removes one whole category of back-and-forth; when the data provenance question gets answered cleanly on the first ask, the review cycle doesn't stall waiting for a second or third follow-up email that takes four days to get answered because everyone's in a different department.

What We're Actually Changing About Our Own Process

The practical upshot is that we've rebuilt how far in advance we start campaigns, and we've had some uncomfortable conversations with clients who are used to faster cycles from non-healthcare verticals. A campaign that would take two weeks end-to-end for a fintech client now needs closer to five or six weeks for a healthcare client if it's going through a hospital system's compliance apparatus, and honestly sometimes longer than that if the campaign season overlaps with something like an open enrollment period when legal teams are already buried.

We've also started front-loading compliance conversations much earlier than we used to — sometimes before copy is even written. Instead of drafting messaging and then sending it into review hoping it clears, we're now getting compliance stakeholders to weigh in on claim language and targeting logic at the concept stage. It feels slower on paper, but it actually saves time overall because it avoids the worst outcome, which is a full rewrite after ten days sitting in a queue.

There's a version of this that's frustrating, and there's a version that's just the new baseline we have to plan around. We've landed mostly on the second interpretation. The healthcare buyers we're reaching are more skeptical and more scrutinized than they were three years ago, which means the campaigns reaching them have to survive a heavier vetting process before they ever land in an inbox. That's not a reason to slow down our thinking — it's a reason to start it earlier. The teams that are struggling right now aren't the ones facing tougher compliance review. They're the ones still planning as if it's 2022.